Janssen Research & Development LLC

November 11, 2019November 11, 2019

1st Patient Dosed in Phase 2 Trial of Investigational PTG-200 for Crohn’s Disease, Protagonist Announces

News

The first patient has been dosed in Protagonist Therapeutics’ Phase 2 clinical trial of PTG-200 for the treatment of moderate to severe Crohn’s disease, the company announced. Still recruiting at ... Read more

October 22, 2015October 22, 2015

Crohn’s Disease Therapy STELARA Showed Efficacy in Phase III Trial

News

Results on a pivotal Janssen Research & Development, LLC-commissioned Phase III clinical trial, called UNITI-2, on STELARA® (ustekinumab) for moderate to severe Crohn’s disease were recently reported and provided the first evidence ... Read more